Paradigm4 has signed an agreement with 54Gene allowing the latter to use the former’s Reveal Biobank App to explore, characterise and query 54Gene’s African Health Information Ecosystem, which is a curated data source of clinical phenotype and genetic information from which insights can be generated to assist the development of treatments and diagnostics.
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.
